BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250708
DTEND;VALUE=DATE:20250711
DTSTAMP:20260515T061253
CREATED:20250404T111858Z
LAST-MODIFIED:20250404T111858Z
UID:40858-1751932800-1752191999@www.pharmajournalist.com
SUMMARY:ESG in Life Sciences Summit West
DESCRIPTION:The ESG in Life Sciences Summit West – Mastering ESG Compliance & Strategic Sustainability in Life Sciences in 2025. \nAs ESG becomes a key differentiator for securing business and investment\, life sciences companies are ramping up sustainability efforts – expanding teams\, funding new initiatives\, and integrating ESG into corporate strategy. Yet\, with shifting global reporting requirements\, the new administration’s stance on sustainability\, and the impact of CSRD on U.S. operations\, many companies are struggling to find the golden ticket on how they can future-proof ESG initiatives and ensure accuracy in reporting? \nAt the same time\, mounting pressure from investors\, consumers\, and employees to accelerate environmental and social initiatives is leaving many searching for the most effective strategies to navigate the evolving ESG landscape. \nFollowing the success of our Boston and European editions\, the ESG in Life Sciences Summit West is bringing together senior leaders in ESG\, Sustainability\, Compliance\, Procurement\, Supply Chain\, and Finance from across the West Coast to: \n\nDecode the impact of evolving U.S. and EU regulations on ESG reporting\nDrive sustainable supply chain transformation\nOptimize ESG strategies for business growth\n\nJoin us in driving the future of Life Sciences sustainability – turning ambition into action\, compliance into opportunity\, and responsibility into lasting impact for people and the planet! Find out more here: https://ter.li/oggmq8
URL:http://www.pharmajournalist.com/event/esg-in-life-sciences-summit-west/
LOCATION:The Clift Royal Sonesta San Francisco\, 495 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250708
DTEND;VALUE=DATE:20250711
DTSTAMP:20260515T061253
CREATED:20250409T113017Z
LAST-MODIFIED:20250409T113017Z
UID:40910-1751932800-1752191999@www.pharmajournalist.com
SUMMARY:3rd ADC Toxicity Summit
DESCRIPTION:“Toxicity is the killer of ADCs” and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose limiting toxicities\, the industry must address key hurdles in preclinical models\, patient selection\, ADC design\, and cross-disciplinary communication to accelerate the next wave of safer\, more effective ADCs. \nThe 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology\, pharmacology\, translational science\, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing\, predicting\, and mitigating toxicities to enhance ADC safety and clinical translation. \nTo know more visit: https://ter.li/57358v
URL:http://www.pharmajournalist.com/event/3rd-adc-toxicity-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250714
DTEND;VALUE=DATE:20250717
DTSTAMP:20260515T061253
CREATED:20250214T115327Z
LAST-MODIFIED:20250214T115819Z
UID:40483-1752451200-1752710399@www.pharmajournalist.com
SUMMARY:3rd Obesity & Weight Loss Summit
DESCRIPTION:The 3rd Obesity & Weight Loss Summit has been announced and is set to ignite the field.  The summit will unite experts to harness novel targets and GLP combination therapies to improve efficacy\, tolerability\, and longer lasting clinical outcomes. \n \nJoin us at this unique\, industry-led summit to: \n\nDiscover groundbreaking combination therapies and novel targets to minimize and manage side effects to improve patient tolerability with Boehringer Ingelheim and Altimmune\nExplore innovative approaches for preserving muscle mass whilst still achieving significant weight loss to prevent sarcopenia with Regeneron and iBio\nInvestigate cutting-edge advancements in drug delivery technologies\, including long-acting formulations and novel administration routes for simpler patient use with Biolexis and Syntis Bio\nLearn strategies to drive long-term weight management success by personalizing treatment for more prolonged patient continuation and satisfaction with Prive Bio and Fractyl Therapeutic\n\nHear from the titans of the pharmaceutical industry – Eli Lilly\, Novo Nordisk\, AstraZeneca\, Altimmune\, High Tide Therapeutics\, RenBio\, and many more – as they share their groundbreaking research and strategies for developing more effective\, tolerable\, and long-lasting weight management solutions. \nObesity rates are increasing\, and the pressure is on for real change. Don’t miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations\, and be part of the solution. The future of weight loss treatment is being written now – be there! \nFor more information\, view the full Event Guide here: https://ter.li/rish42
URL:http://www.pharmajournalist.com/event/3rd-obesity-weight-loss-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250715
DTEND;VALUE=DATE:20250718
DTSTAMP:20260515T061253
CREATED:20250409T111422Z
LAST-MODIFIED:20250411T115959Z
UID:40893-1752537600-1752796799@www.pharmajournalist.com
SUMMARY:5th Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Building on recent breakthroughs in gene therapy\, 2025 is poised for major advancements in cell transplants\, gamma secretase inhibitors\, anti-inflammatory programs\, and more to address the growing unmet need for more transformative hearing loss treatments. \n \nWith an aging population and an urgent need to restore a greater spectrum of hearing abilities beyond the scope of current device-based interventions\, there has never been a more critical time for the field to unite and drive progress. \nCoined by industry as the only meeting of its kind\, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical\, translational\, and clinical bottlenecks\, the 5th Inner Ear Disorders Therapeutics Summit returns as your definitive forum to benchmark learnings from past failures and ignite renewed optimism into the hearing loss therapeutic landscape. \nWith pioneering insights from Regeneron\, Biogen\, Acousia\, Rinri\, Ting Therapeutics\, Lineage Cell Therapeutics\, Gateway and more\, join 50+ of your peers to: \n\nAdvance translatable models to recapitulate complex human inner ear pathophysiology\nDeepen knowledge of molecular and genetic pathways underlying age-related\, noise-induced\, and congenital hearing loss to uncover druggable pathways\nEvaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations\nOvercome translational challenges of bringing advanced therapies\, including small molecule and cell-based approaches\, to the clinic\nUncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants\nHear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space\n\nJoin this unparalleled forum of biotech innovators\, pharma stakeholders\, medical device manufacturers\, and leading academics in a collaborative atmosphere to advance otoprotection\, hearing restoration\, and gene therapy R&D and transform the treatment of hearing loss. \nFind out more in our brochure: https://ter.li/22rawz
URL:http://www.pharmajournalist.com/event/5th-inner-ear-disorders-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250721
DTEND;VALUE=DATE:20250724
DTSTAMP:20260515T061253
CREATED:20250304T115052Z
LAST-MODIFIED:20250304T115052Z
UID:40636-1753056000-1753315199@www.pharmajournalist.com
SUMMARY:5th mRNA-Based Therapeutics Summit
DESCRIPTION:The mRNA field is on the cusp of revolutionary change\, with cancer vaccines\, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidates and developmental progress towards clinical and commercial approval. \nTo shine light on emerging areas and the latest progress\, the 5th mRNA-Based Therapeutics Summit returns to Boston as the world’s largest\, end-to-end mRNA conference\, gathering 350+ global stakeholders\, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA\, Circular RNA & SaRNA fields including Moderna\, Pfizer\, BioNTech\, Grann Pharmaceuticals\, Celestial Therapeutics. \nDiscover the realms of new infectious disease platforms\, combating oncological targets and cell therapies across 4 dedicated tracks of content in Discovery\, Pre-Clinical Development\, Clinical Development and Manufacturing & CMC\, as your one-stop-shop scientific content and partnering forum to aid the progress of pipelines in 2025 towards the clinic and ultimately patients in need. \nDownload the event guide for full details: https://ter.li/esarrv
URL:http://www.pharmajournalist.com/event/5th-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250722
DTEND;VALUE=DATE:20250724
DTSTAMP:20260515T061253
CREATED:20250430T133531Z
LAST-MODIFIED:20250430T133531Z
UID:41019-1753142400-1753315199@www.pharmajournalist.com
SUMMARY:13th Tumor Models Summit Boston
DESCRIPTION:This July\, the 13th Tumor Models Summit Boston returns\, uniting 180+ preclinical and translational experts from biopharma and solution providers. \nThis year’s dual-track program will empower you and your team to implement reproducible\, predictive oncology models\, and bridge the translational gap in a time- and cost-effective manner. \nExpect to gain exclusive insights into: \n\nThe latest applications of tumoroids\, patient-derived in vivo\, ex vivo\, in silico and genetically engineered models\nOptimized protocols to humanize complex in vitro and mouse models\nApplying reverse translation and clinical learnings to better stratify patients\, focus treatment regimens\, and improve patient outcomes\nPractical applications of digital pathology and spatial biology to advance your model selection strategy\n\nEvent information and quick links: \n\nLocation: Westin Boston Seaport District\, Boston\, MA\nDates: July 22-23\, 2025\nEvent Guide: https://ter.li/dz9th5\nRegistration (FREE* for biopharma!): https://ter.li/d6bden\n\n*Subject to terms and conditions\, visit the website to learn more: https://ter.li/d6bden
URL:http://www.pharmajournalist.com/event/13th-tumor-models-summit-boston/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061253
CREATED:20250321T130027Z
LAST-MODIFIED:20250321T130140Z
UID:40739-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:4th Targeted Radiopharmaceuticals Summit US
DESCRIPTION:As demand for radiopharmaceuticals rises\, the industry is focused on strengthening isotope supply\, improving patient access\, and accelerating therapeutic development. \n \nJoin us at the 4th Targeted Radiopharmaceuticals Summit US in San Diego this July for the premier platform dedicated to radiopharmaceutical therapeutics and theranostics\, featuring: \n\n50+ Expert Speakers from leading biotech\, pharma\, and research institutions\, including Ratio Tx\, Abdera\, Alpha-9\nOncology\, Novartis\, AstraZeneca\, UCLA\, UCSF\, and more\n275+ Industry Attendees driving advancements from bench to bedside\n11+ Hours of Networking with top professionals\n3 Dedicated Tracks: Discovery & Preclinical\, Translational & Clinical\, and Clinical & Supply Chain\, curated to address key challenges\n\nOffering a tightly focused agenda dedicated to industry-specific topics\, this event is designed to advance approvals and commercialization. \nExplore critical areas such as isotope supply\, clinical development\, regulatory clarity\, novel molecule design\, investment and funding and much more. \nDon’t miss this essential event for anyone involved in the radiopharmaceuticals space! \nView the exclusive program here.
URL:http://www.pharmajournalist.com/event/4th-targeted-radiopharmaceuticals-summit-us/
LOCATION:The Hyatt Regency La Jolla\, 3777 La Jolla Village Drive\, San Diego\, CA\, 92122\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061253
CREATED:20250516T043336Z
LAST-MODIFIED:20250516T043336Z
UID:41089-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:Operationalize: Expanded Access Programs Summit West
DESCRIPTION:The Operationalize: Expanded Access Programs Summit West is coming to San Francisco! (July 29-31). \nFollowing the successful Boston and London meetings\, the Operationalize Expanded Access Programs Summit West is uniting stakeholders executing Early Access\, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need. \nThis Summit is the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies! \nFind out more at our website: https://ter.li/9ft05e. \nJoin 60+ experts\, from Eli Lilly\, Gilead\, Ultragenyx\, Daiichi Sankyo and more for three jam-packed days in San Francisco this July. Get exclusive insights\, real-world case studies and cutting-edge strategies to supercharge your Expanded Access Programs.
URL:http://www.pharmajournalist.com/event/operationalize-expanded-access-programs-summit-west/
LOCATION:The Clift Royal Sonesta\, 495 Geary Street\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061253
CREATED:20250520T095035Z
LAST-MODIFIED:20250520T095035Z
UID:41125-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:5th Fc-Mediated Function Summit
DESCRIPTION:The landscape of Fc-mediated therapies is undergoing a radical transformation\, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification. \nThis year\, we’re evaluating the cutting-edge of Fc biology and engineering\, diving deep into the game-changing potential of novel Fc modifications\, bispecific formats\, and targeted effector functions to revolutionize the treatment of cancer\, autoimmune diseases\, and beyond. Hear from the titans of the pharmaceutical industry\, including AbbVie\, Novartis\, and UCB as well as innovative biotechs including Seismic Therapeutics\, Paradigm Immunotherapies\, and many more – as they share their groundbreaking research and strategies for developing more effective\, safer\, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky\, and the pressure is on to continue this success and develop best-in-class treatments. \nWhy Attend? \n\nNavigate the latest insights into Fc receptor interactions and unlock the potential of precisely engineered antibodies for targeted efficacy and enhanced safety profiles\nConfront the challenges in therapeutic antibody development head-on by exploring novel Fc engineering strategies and optimizing treatment outcomes across diverse disease indications\nHear from 22+ industry luminaries and thought leaders\, including Sally Ward and Richard Blumberg\, and a multitude of companies who are pushing the boundaries of antibody engineering and Fc-mediated therapeutics\, including Argenx\, UCB\, and Boehringer Ingelheim\n\nDon’t miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function\, forge crucial collaborations\, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it! \nRegister now.
URL:http://www.pharmajournalist.com/event/5th-fc-mediated-function-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061253
CREATED:20250613T092615Z
LAST-MODIFIED:20250613T092615Z
UID:41264-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:5th Next Generation Gene Therapy Vectors Summit
DESCRIPTION:The 5th Next Generation Gene Therapy Vectors Summit \n \nRecent announcements from major pharmaceutical companies scaling back their AAV gene therapy pipelines have raised concerns across the field. However\, this is not the end. It is an opportunity to reset\, refocus\, and rise to the challenge. While issues such as liver toxicity\, pre-existing antibodies\, and high manufacturing costs remain significant\, so too does the unmatched potential of AAV vectors. From their ability to cross the blood-brain barrier to delivering single-stranded DNA for single-dose cures\, AAV continues to offer enormous therapeutic promise. \nThe 5th Next Generation Gene Therapy Vectors Summit returns to Boston this September to spotlight the scientists and leaders who are continuing to innovate in vector design. This meeting is designed for those who understand that strategic setbacks can often pave the way for transformative breakthroughs\, as we saw in the early development of ADCs. \nOver the course of 3 days\, the summit will bring together experts in vector engineering\, translational science\, and clinical development to explore how the field can advance in a more refined and resilient direction. Attendees will hear from thought leaders such as Daniel Cohen (Spark Therapeutics)\, Eric Kelsic (Dyno Therapeutics)\, Jorge Santiago-Ortiz (Apertura Gene Therapy)\, Lolita Petit (Coave Therapeutics)\, Ralf Schmid (Novartis)\, and Roxanne Croze (4D Molecular Therapeutics). \nThe program will explore the latest innovations in capsid engineering\, novel strategies to overcome immune responses\, scalable systemic delivery technologies\, and key clinical insights that can shape future development pipelines. \nWhether your focus is vector optimization\, CMC\, or clinical translation\, this summit provides a valuable opportunity to connect with the experts and technologies leading the next phase of gene therapy innovation. Join the community in Boston this July and help shape a safer\, smarter\, and more successful future for AAV. \nFind Out More Here: https://ter.li/8qkdsh
URL:http://www.pharmajournalist.com/event/5th-next-generation-gene-therapy-vectors-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR